



Mi-Kyung Kim

Keimyung University, Korea

• Education

Period	Affiliation	Position
– 2006-2008	Keimyung University Graduate School	Ph.D.
– 2004-2006	Keimyung University Graduate School	M.S.
– 1996-2002	Keimyung University School of Medicine	M.D.

• Affiliations / Experience

Period	Affiliation	Position
– 2024-Present	Keimyung University School of Medicine	Professor
– 2018-2023	Keimyung University School of Medicine	Associate Professor
– 2016-2017	Sanford Burnham Prebys Medical Discovery Institute	Visiting Researcher
– 2011-2018	Keimyung University School of Medicine	Assistant Professor

• Committee Memberships

- Korean diabetes Association
- Korean Endocrine Society
- Korean Society for the Society of Obesity
- The Korean Association of Internal Medicine

• Publications

- Diabetic Kidney Disease Fact Sheet in Korea. Kim NH, Seo MH, Jung JH, Han KD, Kim MK, Kim NH; Diabetic Kidney Disease Research Group of the Korean Diabetes Association. *Diabetes Metab J*
- Strategies to Maintain the Remission of Diabetes Following Metabolic Surgery. Kim MK, Kim HS. *J Metab Bariatr Surg. Dec;12(2): 26-34*
- Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. Seo HY, Lee SH, Park JY, Han E, Han S, Hwang JS, Kim MK*, Jang BK*. *PLoS One. 24;18(8):e0290532*
- Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity. Han E, Kim MK*, Lee HW, Ryu S, Kim HS, Jang BK, Suh Y. *Obesity (Silver Spring). 30(12):2440-2449*
- Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. Seo HY, Lee SH, Han E, Hwang JS, Han S, Kim MK*, Jang BK*. *Int J Mol Sci. 23(19):11636*